Get the Stockscreener App
2.95
0.67%
-0.02
Pre-market:
2.95
Tharimmune Inc stock is traded at $2.95, with a volume of 84,090.
It is down -0.67% in the last 24 hours and up +3.87% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$2.97
Open:
$3
24h Volume:
84,090
Relative Volume:
0.01
Market Cap:
$17.42M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.2321
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
-4.53%
1M Performance:
+3.87%
6M Performance:
+70.52%
1Y Performance:
+3.51%
1-Day Range:
$2.85
$3.00
1-Week Range:
$2.85
$3.2099
52-Week Range:
$0.952
$9.08
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
2.95 | 22.60M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tharimmune Inc Stock (THAR) Latest News
Tharimmune Amends Warrants Agreement to Boost Liquidity - MSN
What insider trading reveals about Tharimmune Inc. stockWeekly Market Outlook & Daily Price Action Insights - newser.com
Will Tharimmune Inc. stock sustain high P E ratios2025 Earnings Impact & Short-Term High Return Ideas - newser.com
Does Tharimmune Inc. fit your quant trading model2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
What the charts say about Tharimmune Inc. todayTrade Entry Report & Consistent Profit Alerts - newser.com
Using data models to predict Tharimmune Inc. stock movementMarket Sentiment Report & Free Growth Oriented Trading Recommendations - newser.com
Will earnings trigger a reversal in Tharimmune Inc.Quarterly Investment Review & Safe Entry Trade Reports - newser.com
Will Tharimmune Inc. continue its uptrendWeekly Profit Summary & Weekly High Conviction Trade Ideas - newser.com
Why analysts upgrade Tharimmune Inc. stock2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Is Tharimmune Inc. stock attractive for retirement portfoliosPortfolio Growth Summary & Long-Term Growth Portfolio Plans - newser.com
Is Tharimmune Inc. still worth holding after the dipOil Prices & Low Drawdown Investment Strategies - newser.com
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments - Pueblo Chieftain
What analysts say about Tharimmune Inc stockSector-Based Investing & Maximize Returns With Insights - earlytimes.in
How resilient is Tharimmune Inc. stock in market downturns2025 Breakouts & Breakdowns & Safe Investment Capital Preservation Plans - newser.com
Can Tharimmune Inc. stock continue upward trendQuarterly Growth Report & Reliable Breakout Forecasts - fcp.pa.gov.br
Tharimmune’s New Study on TH104: A Potential Game-Changer for PBC Treatment - TipRanks
Tharimmune, Inc.Common Stock (NQ: THAR - FinancialContent
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):